Core Insights - BrightSpring Health Services, Inc. (BTSG) has made significant investments in process improvements and technology enhancements, leading to better care delivery efficiency and patient outcomes [1][4] - The company has achieved high ratings across various segments, with over 80% of Home Health branches rated 4 stars or better and patient satisfaction nearing 90% [1][8] Home Health Segment - Over 80% of Home Health branches achieved a 4-star rating or better, with declining 60-day hospitalization rates [1][8] - Patient satisfaction in the Home Health segment is approaching 90% [1] Hospice Operations - Hospice operations have outperformed, with visit frequency and time spent with patients exceeding the national average by 50% [2] - Quality index scores in the Hospice segment have reached record highs [2] Rehabilitation and Personal Care Segments - Patient satisfaction in the Rehab segment remains strong at 98% [2] - The Personal Care segment achieved its highest-ever rating with a satisfaction score of 4.6 out of 5 [2] Community Living and Infusion Segments - Community Living recorded its lowest number of audit findings to date, which is 40% better than the industry average [2] - The Infusion segment reported a 96% therapy completion discharge rate and a 95% patient satisfaction score [3] Operational Metrics - Home and Community Pharmacy Services achieved near-perfect operational metrics, including 99.999% dispense accuracy and 99% order completeness [3] Competitive Landscape - Amedisys (AMED) maintains a focus on clinical distinction, achieving an average Quality of Patient Care star rating of 4.18 across all providers, with 88% of care centers rated 4 stars or higher [5] - Addus HomeCare Corporation (ADUS) has launched the Care Advantage Program to enhance preventive care and patient satisfaction through a tech-enabled approach [6] Stock Performance and Valuation - Shares of BrightSpring have gained 104.1% in the past year, significantly outperforming the industry, which saw a decline of 21.7% [7] - BTSG trades at a forward price-to-earnings ratio of 21.59, above the industry's 14.25 [9] Earnings Estimates - The Zacks Consensus Estimate for BTSG's earnings has been on the rise over the past 30 days, with current quarter estimates at $0.22 and next year at $1.19 [10][11]

Group 1: Momentum Investing Overview - Momentum investing contrasts with the traditional "buy low and sell high" strategy, focusing instead on "buying high and selling higher" to capitalize on fast-moving stocks [1] - Identifying the right entry point for trending stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] Group 2: Investment Strategy - A safer approach involves investing in bargain stocks that exhibit recent price momentum, utilizing tools like the Zacks Momentum Style Score to identify such opportunities [2] - The 'Fast-Paced Momentum at a Bargain' screen helps in spotting fast-moving stocks that remain attractively priced [2] Group 3: BrightSpring Health Services, Inc. (BTSG) Analysis - BrightSpring Health Services, Inc. (BTSG) has shown significant recent price momentum, with a four-week price change of 37.3%, indicating growing investor interest [3] - Over the past 12 weeks, BTSG has gained 20.5%, demonstrating its ability to deliver positive returns over a longer timeframe [4] - BTSG has a beta of 2.06, suggesting it moves 106% higher than the market in either direction, indicating fast-paced momentum [4] Group 4: Valuation and Earnings Estimates - BTSG has a Momentum Score of A, suggesting it is an opportune time to invest in the stock for potential success [5] - The stock has a Zacks Rank 2 (Buy) due to an upward trend in earnings estimate revisions, which typically attracts more investor interest [6] - BTSG is trading at a Price-to-Sales ratio of 0.35, indicating it is relatively cheap, as investors pay only 35 cents for each dollar of sales [6] Group 5: Additional Investment Opportunities - Besides BTSG, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, presenting further investment opportunities [7] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [8]

Company Overview - Amedisys (AMED) is part of the Medical group, which consists of 997 companies and is currently ranked 5 within the Zacks Sector Rank [2] - Amedisys operates in the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and is ranked 73 in the Zacks Industry Rank [5] Performance Analysis - Year-to-date, Amedisys has returned 3.1%, outperforming the average loss of 6.8% in the Medical sector [4] - The Zacks Consensus Estimate for Amedisys's full-year earnings has increased by 1.5% over the past quarter, indicating improved analyst sentiment [3] - In comparison, BrightSpring Health Services, Inc. has returned 34.6% year-to-date and has a consensus EPS estimate increase of 23.8% over the past three months [4][5] Industry Context - The Medical - Outpatient and Home Healthcare industry has seen an average gain of 2.6% this year, with Amedisys performing better than this average [5] - The broader Medical Services industry, which includes BrightSpring Health Services, has declined by 5.5% this year and is ranked 65 [6]

Summary of BrightSpring Health Services (BTSG) Conference Call Company Overview - **Company**: BrightSpring Health Services (BTSG) - **Industry**: Healthcare, specifically home and community health care and pharmacy services Key Points and Arguments Financial Performance - **Q1 Performance**: The company reported a strong Q1, beating expectations and raising guidance, primarily driven by specialty pharmacy performance [2][4] - **Historical Growth**: The company has achieved a mid-teens CAGR in EBITDA and revenue over nearly a decade, with broad-based growth across service lines [4][5] - **Volume Growth**: Volume growth is supported by quality service across all lines, operational efficiencies, and accretive mergers and acquisitions (M&A) [5][6] Specialty Pharmacy Growth - **Oncology and Rare Diseases**: Specialty pharmacy, particularly in oncology and rare diseases, has seen significant growth, with a reported 30% growth year-over-year for the last three years [9][10] - **Innovation in Therapies**: Continuous innovation in therapies is driving demand, with expectations of 12 to 18 new products entering the market in the next 18 months [13] Service Lines and Market Dynamics - **Home and Community Focus**: BrightSpring aims to be a leading provider in home and community health care, with strong demand for services [6][17] - **Provider Business Growth**: The provider business experienced around 10% year-over-year growth, even with fewer days in the quarter compared to the previous year [7] - **Pharmacy Services**: The pharmacy business is expected to grow in the mid-single digits, with potential for double-digit growth in specific areas like infusion and specialty oncology [25][26] M&A Strategy - **Acquisition Focus**: The company has executed several smaller tuck-in acquisitions and plans to continue this strategy, particularly in home health, hospice, and rehab [15][58] - **Community Living Divestiture**: The divestiture of the community living business is expected to close by the end of the year, which will help improve leverage ratios [54][55] Regulatory Environment - **Impact of Inflation Reduction Act (IRA)**: The IRA has both positive and negative implications for the company, particularly concerning drug pricing and access to medications [35][38] - **Tariffs on Drugs**: Potential tariffs on drugs are being monitored, with the company confident in its supply chain resilience due to a significant portion of drugs being sourced domestically [42][46] Operational Efficiency - **EBITDA Margin Target**: The company targets a 6% EBITDA margin, focusing on lean operations and technology to enhance efficiency across business lines [34] - **Integrated Care Opportunities**: The company is exploring integrated care models that combine various services to improve patient outcomes and reduce hospitalizations [31][33] Future Outlook - **Leverage Reduction**: The company aims to reduce leverage to around three times by the end of the year, supported by cash generation and growth [55][56] - **Market Positioning**: BrightSpring is positioned to leverage its scale and operational capabilities to navigate regulatory changes and market dynamics effectively [50][51] Additional Important Insights - **Quality and Compliance**: The company emphasizes its commitment to quality and compliance, which has resulted in better performance metrics compared to industry averages [22] - **Patient-Centric Approach**: The focus on delivering high-quality, patient-centered services is seen as a key driver for growth and market share [20][21]

Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with BrightSpring Health Services, Inc. (BTSG) currently holding a Momentum Style Score of A [2] Group 2: Zacks Rank and Performance - BTSG has a Zacks Rank of 1 (Strong Buy), indicating strong potential for outperformance in the market [3] - Stocks rated Zacks Rank 1 and 2 with Style Scores of A or B have historically outperformed the market over the following month [3] Group 3: Price Performance - BTSG shares have increased by 23.35% over the past week, significantly outperforming the Zacks Medical Services industry, which rose by only 0.63% [5] - Over the past month, BTSG's price change is 29.35%, compared to the industry's 0.88% [5] - In the last quarter, BTSG shares increased by 1.99%, and over the past year, they have gained 95.66%, while the S&P 500 has moved -5.75% and 10.63%, respectively [6] Group 4: Trading Volume - BTSG's average 20-day trading volume is 2,067,688 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 5: Earnings Outlook - Over the past two months, four earnings estimates for BTSG have been revised upwards, with no downward revisions, increasing the consensus estimate from $0.69 to $0.98 [9] - For the next fiscal year, four estimates have also moved upwards without any downward revisions [9] Group 6: Conclusion - Given the strong performance metrics and positive earnings outlook, BTSG is positioned as a 1 (Strong Buy) stock with a Momentum Score of A, making it a compelling investment option [11]

Core Viewpoint - BrightSpring Health Services, Inc. (BTSG) shows potential as a strong investment opportunity due to significant revisions in earnings estimates, indicating an improving earnings outlook [1][11]. Earnings Estimate Revisions - Analysts have become increasingly optimistic about the earnings prospects of BrightSpring Health Services, leading to higher earnings estimates, which are expected to positively impact the stock price [2]. - The consensus earnings estimate for the current quarter has risen to $0.20 per share, reflecting a 100% increase from the previous year [7]. - For the full year, the earnings estimate is projected at $0.98 per share, representing a year-over-year increase of 75% [8]. - Over the past month, the consensus estimate for the current year has increased by 35.24%, with four estimates moving up and no negative revisions [9]. Zacks Rank and Performance - BrightSpring Health Services has achieved a Zacks Rank 1 (Strong Buy), indicating strong potential for outperformance based on favorable estimate revisions [10]. - Historically, stocks with a Zacks Rank 1 have generated an average annual return of +25% since 2008, suggesting a strong correlation between earnings estimate revisions and stock performance [3][10]. Stock Performance - The stock has experienced a 27% gain over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects [11].

Group 1: BrightSpring Health Services, Inc. (BTSG) - BrightSpring Health Services is a home and community-based healthcare services platform with a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings increased by 18.8% over the last 60 days [1] - BrightSpring's shares gained 3.4% over the last three months, while the S&P 500 declined by 7.6% [1] - The company has a Momentum Score of B [1] Group 2: United Bankshares, Inc. (UBSI) - United Bankshares is a financial holding company that primarily provides commercial and retail banking products and services, also holding a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings increased by 2.9% over the last 60 days [2] - United's shares gained 4.7% over the last month, compared to the S&P 500's advance of 2.7% [2] - The company possesses a Momentum Score of A [2]

Group 1 - Momentum investing contrasts with the traditional strategy of "buy low and sell high," focusing instead on "buying high and selling higher" [1] - Identifying the right entry point for fast-moving stocks can be challenging, as they may lose momentum if future growth does not justify their high valuations [1] - A safer investment approach involves targeting bargain stocks that exhibit recent price momentum [2] Group 2 - BrightSpring Health Services, Inc. (BTSG) is highlighted as a strong candidate for investment, showing a four-week price change of 27% [3] - BTSG has gained 6.3% over the past 12 weeks, indicating its ability to deliver positive returns over a longer timeframe [4] - The stock has a beta of 2.06, suggesting it moves 106% higher than the market in either direction, reflecting fast-paced momentum [4] Group 3 - BTSG has a Momentum Score of A, indicating a favorable time to invest based on momentum [5] - The stock has a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which attract more investor interest [6] - BTSG is trading at a Price-to-Sales ratio of 0.35, suggesting it is undervalued at 35 cents for each dollar of sales [6] Group 4 - BTSG appears to have significant potential for growth at a fast pace, alongside other stocks that meet the 'Fast-Paced Momentum at a Bargain' criteria [7] - There are over 45 Zacks Premium Screens available to help identify winning stock picks based on various investing styles [8]

Group 1 - BrightSpring Health Services, Inc. (BTSG) has seen the Zacks Consensus Estimate for its current year earnings increasing by 18.8% over the last 60 days [1] - Norwood Financial Corp. (NWFL) has experienced a nearly 4% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Monro, Inc. (MNRO) has had a 2.5% increase in the Zacks Consensus Estimate for its next year earnings over the last 60 days [2] - United Bankshares, Inc. (UBSI) has seen a 5.7% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Immunocore Holdings plc (IMCR) has experienced a 4.5% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3]

Company Overview - BrightSpring Health Services, Inc. (BTSG) is part of the Medical group, which consists of 1001 companies and currently ranks 5 within the Zacks Sector Rank [2] - The company is classified under the Medical Services industry, which includes 58 individual companies and is ranked 66 in the Zacks Industry Rank [6] Performance Metrics - Year-to-date, BTSG has increased by approximately 28.2%, while the average performance of Medical stocks has declined by 5.5% [4] - The Zacks Consensus Estimate for BTSG's full-year earnings has risen by 0.2% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [4] Comparative Analysis - Another Medical stock, Cencora (COR), has also outperformed the sector with a year-to-date return of 29.4% and a Zacks Rank of 2 (Buy) [5] - Both BrightSpring Health Services, Inc. and Cencora are performing better than their respective industry averages, with the Medical Services industry averaging a loss of 3% this year [6] Investment Outlook - Investors interested in Medical stocks should closely monitor BrightSpring Health Services, Inc. and Cencora for potential continued strong performance [7]